Recent studies have discovered distinct genomic mechanisms of PD-L1 upregulation that coincides with limited but encouraging data that indicate that patients with ALCL may well benefit from treatment with anti-PD1 ICIs. Here, PDCD1 is linked to anaplastic large cell lymphoma.